L-5-Hydroxytryptophan-d3-1

CAT:
804-HY-B1716S1
Size:
1 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
L-5-Hydroxytryptophan-d3-1 - image 1

L-5-Hydroxytryptophan-d3-1

  • UNSPSC Description:

    L-5-Hydroxytryptophan-d3-1 is the deuterium labeled L-5-Hydroxytryptophan[1]. L-5-Hydroxytryptophan (L-5-HTP), a naturally occurring amino acid and a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, is the immediate precursor of the neurotransmitter serotonin and a reserpine antagonist[2]. L-5-Hydroxytryptophan (L-5-HTP) is used to treat fibromyalgia, myoclonus, migraine, and cerebellar ataxia[3][4][5][6].
  • Target Antigen:

    Endogenous Metabolite
  • Type:

    Isotope-Labeled Compounds
  • Related Pathways:

    Metabolic Enzyme/Protease
  • Applications:

    Metabolism-protein/nucleotide metabolism
  • Field of Research:

    Metabolic Disease
  • Solubility:

    10 mM in DMSO
  • Smiles:

    OC([C@@]([H])(CC(C1=C2[2H])=CNC1=C(C([2H])=C2O)[2H])N)=O
  • Molecular Weight:

    223.24
  • References & Citations:

    [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.|[2]ARVID CARLSSON, et al. 3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists. Nature 180, page1200 (1957).|[3]Caruso I, et al. Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res. 1990 May-Jun18(3):201-9.|[4]Thal LJ, et al. Treatment of myoclonus with L-5-hydroxytryptophan and carbidopa: clinical, electrophysiological, and biochemical observations. Ann Neurol. 1980 Jun7(6):570-6.|[5]Boiardi A, et al. 5-OH-Tryptophane in migraine: clinical and neurophysiological considerations. J Neurol. 1981225(1):41-6.|[6]Trouillas P, et al. Improvement of cerebellar ataxia with levorotatory form of 5-hydroxytryptophan. A double-blind study with quantified data processing. Arch Neurol. 1988 Nov45(11):1217-22.
  • Shipping Conditions:

    Room temperature
  • Clinical Information:

    No Development Reported